RegenETP Inc.
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, rep… Read more
RegenETP Inc. (RGTPQ) - Net Assets
Latest net assets as of March 2023: $12.42 Million USD
Based on the latest financial reports, RegenETP Inc. (RGTPQ) has net assets worth $12.42 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.05 Million) and total liabilities ($5.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.42 Million |
| % of Total Assets | 68.82% |
| Annual Growth Rate | -24.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.56 |
RegenETP Inc. - Net Assets Trend (2019–2022)
This chart illustrates how RegenETP Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RegenETP Inc. (2019–2022)
The table below shows the annual net assets of RegenETP Inc. from 2019 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $16.62 Million | -13.65% |
| 2021-12-31 | $19.24 Million | -29.61% |
| 2020-12-31 | $27.34 Million | -29.75% |
| 2019-12-31 | $38.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RegenETP Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8087400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.04% |
| Other Components | $532.84 Million | 3206.41% |
| Total Equity | $16.62 Million | 100.00% |
RegenETP Inc. Competitors by Market Cap
The table below lists competitors of RegenETP Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clean Energy Transition Inc.
V:TRAN
|
$1.11 Million |
|
Media Central Corporation Inc
PINK:FBOP
|
$1.11 Million |
|
PT Utama Radar Cahaya Tbk
JK:RCCC
|
$1.11 Million |
|
Acma Ltd
F:AAX1
|
$1.11 Million |
|
Williamson Magor & Company Limited
NSE:WILLAMAGOR
|
$1.11 Million |
|
CLEARBRIDGE HEALTH LTD
F:5C6
|
$1.11 Million |
|
BLAZE Minerals Ltd
AU:BLZ
|
$1.11 Million |
|
Rimoni
TA:RIMO
|
$1.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RegenETP Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 19,244,000 to 16,618,000, a change of -2,626,000 (-13.6%).
- Net loss of 7,833,000 reduced equity.
- New share issuances of 12,637,000 increased equity.
- Other factors decreased equity by 7,430,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.83 Million | -47.14% |
| Share Issuances | $12.64 Million | +76.04% |
| Other Changes | $-7.43 Million | -44.71% |
| Total Change | $- | -13.65% |
Book Value vs Market Value Analysis
This analysis compares RegenETP Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $35.54 | $0.16 | x |
| 2020-12-31 | $12.46 | $0.16 | x |
| 2021-12-31 | $5.83 | $0.16 | x |
| 2022-12-31 | $2.29 | $0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RegenETP Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -962.29%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.37x
- Recent ROE (-47.14%) is above the historical average (-149.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -237.67% | -1636.46% | 0.11x | 1.38x | $-96.38 Million |
| 2020 | -156.76% | -423.21% | 0.22x | 1.66x | $-45.59 Million |
| 2021 | -156.86% | -321.00% | 0.30x | 1.62x | $-32.11 Million |
| 2022 | -47.14% | -962.29% | 0.04x | 1.37x | $-9.49 Million |
Industry Comparison
This section compares RegenETP Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RegenETP Inc. (RGTPQ) | $12.42 Million | -237.67% | 0.45x | $1.11 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |